To the full analysis
Anthem Biosciences stock: growth
ANTHEM.NSAnthem Biosciences reported $225.79M in revenue for fiscal 2025, up 15.2% on the prior year, up 14.6% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
14.6%
per year from 2021 to 2025, per share 14.6%
Earnings (Annual rate)
9.9%
per year from 2021 to 2025, per share 9.9%
Free cash flow (Annual rate)
42.3%
per year from 2021 to 2025, per share 42.3%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | |
|---|---|
| Revenue | 14.6% |
| Revenue per share | 14.6% |
| Earnings | 9.9% |
| Earnings per share | 9.9% |
| Free cash flow | 42.3% |
| Free cash flow per share | 42.3% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2021 | $130.87M | $43.1M | $18.3M |
| 2022 | $112.34M | $40.94M | $11.84M |
| 2023 | $150.86M | $39.04M | −$16.69M |
| 2024 | $196.05M | $47.96M | $11.02M |
| 2025 | $225.79M | $62.9M | $75.01M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 31 Jul 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.